RE:Nobody wants to get rich slow"On June 25, 2012, Gilles Gagnon became the corporation Chief Executive Officer and during that week, the shares began at $0.09 and ended at $0.10 on very light volume."
$.09 to $.70 in approximately ten years is a 778% return. That return can be attributed to the undervalued base business alone which moved from a business incubator to its own state-of-the-art facility over this period. The base business is solidly profitable with a list of gold plate clients and has grown double digits annually for the last ten years. The distribution deal with C$20 billion market cap Symrise this year further promises to 'accelerate' sales according to the news release. Revenue year-to-date is up 14%.
Many preclinical biotech stocks are currently trading below cash due to inflationary concerns in what has been the worst biotech market in history as inflation has soared. The market wants profitability. A once in a century pandemic has also slowed the pace of development for CZO closing labs, etc., in recent years. The cashflow from the base business has sustained the company and financed the advancement of the pipeline. CZO has been resilient.
As for CZO's development pipeline, preclinical research typically fails or has a long and winding road to the clinic and market. Despite this risk, CZO has advanced a pipeline of opportunities to the clinical trial and commercial goal line over the last ten years. As a stamp of approval for what CZO has achieved at this defining moment Canadian pharma icon Ronnie Miller, from the second largest pharma in the world, recently joined CZO's Board of Directors. He then became Chairman. It is hard to get a bigger name than that in Canadian pharma, period; especially for a microcap.
Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”
The chirping of anonymous posters on this message board about how miserable CZO is should not be taken seriously. They are trolls, period, and have been bashing CZO rain or shine and all the way up.